Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.

5 Feb 2013

Oral toxicity is frequent limitation of mTOR therapy

Oral mucositis is a frequent complication in patients taking mTOR inhibitors and a major reason for dose reductions and discontinuations in clinical trials, according to a review of this class of cancer drugs.

4 Feb 2013

$Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer$

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.

3 Jan 2013

Cytokine rise signals RCC progression

Progression of renal cell carcinoma is frequently preceded by a rise in levels of proangiogenic cytokines, Italian researchers have found.

17 Dec 2012

Nephron-sparing surgery beats ablation for small renal masses

Nephron-sparing surgery is more effective than ablation for the treatment of clinical stage T1a renal masses, research findings show.

17 Dec 2012

Preop features predict pathology of small renal masses

Researchers have identified preoperative clinical and tumor characteristics that predict the risk for malignancy in patients undergoing partial nephrectomy for small renal masses.

17 Dec 2012

Partial nephrectomy maintains renal function in cT1a RCC

Partial nephrectomy offers a similar magnitude of benefit in patients with clinical T1b versus cT1a renal cell carcinoma, Japanese researchers have shown.

17 Dec 2012

Kidney cancer survival rates: an interview with Dr Wong-Ho Chow

There are two major forms of kidney cancer. One is called renal cell cancer, which is an adenocarcinoma that occurs in the renal parenchyma. The other major type is called renal pelvis cancer, which is mostly of transitional cell type and they form in the centre of the kidney where the urine collects.

7 Dec 2012

Researchers discover 29 proteins associated with spread of kidney cancer

Researchers at St. Michael's hospital have identified 29 proteins that are likely to be involved in the spread of kidney cancer. The discovery will help physicians recognize which tumours are going to behave more aggressively and provide those patients with more intensive treatment and closer followup.

7 Dec 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Perfusion of renal masses on MR corresponds to histopathologic diagnosis

A magnetic resonance imaging technique that uses blood as a contrast medium is able to distinguish between different histopathologic diagnoses of solid renal masses based on their perfusion level, claims a team of scientists.

22 Nov 2012

Tumors 'not always greatest mortality risk in RCC patients'

Patients with localized solid kidney tumors may be at greater risk for death from non-cancer-related causes before that from disease progression and cancer-related mortality, say US researchers who developed a comorbidity-based risk prediction model.

22 Nov 2012

Tumour burden predicts prognosis in mRCC

Tumor burden plays an independent prognostic and predictive role in metastatic renal cell carcinoma, a clinical trial shows.

22 Nov 2012

Temsirolimus effective for mRCC patients on hemodialysis

Research findings published in the International Journal of Clinical Oncology suggest that temsirolimus effectively stabilizes disease progression in patients with metastatic renal cell carcinoma undergoing hemodialysis.

22 Nov 2012

Cancer Network, ONCOLOGY present two part primer report on targeted therapies in solid tumors

UBM Medica US announces that Cancer Network and the journal ONCOLOGY are presenting a two part primer report on targeted therapies in solid tumors.

17 Nov 2012

White kidney cancer patients have a survival advantage over blacks

Among patients with the most common form of kidney cancer, whites consistently have a survival advantage over blacks, regardless of patient and tumor characteristics or surgical treatment.

12 Nov 2012

Patient recruitment complete for immatics IMA901 Phase 3 trial for renal cell carcinoma

immatics biotechnologies GmbH, a biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, announced today that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma (RCC). The trial has completed patient inclusion and it is expected that around 345 patients will be randomized across 10 countries in the US and Europe.

8 Nov 2012

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.

18 Oct 2012

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

AVEO Oncology and Astellas Pharma Inc. today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC).

29 Sep 2012

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Oral toxicity is frequent limitation of mTOR therapy

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Cytokine rise signals RCC progression

Nephron-sparing surgery beats ablation for small renal masses

Preop features predict pathology of small renal masses

Partial nephrectomy maintains renal function in cT1a RCC

Kidney cancer survival rates: an interview with Dr Wong-Ho Chow

Researchers discover 29 proteins associated with spread of kidney cancer

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Perfusion of renal masses on MR corresponds to histopathologic diagnosis

Tumors 'not always greatest mortality risk in RCC patients'

Tumour burden predicts prognosis in mRCC

Temsirolimus effective for mRCC patients on hemodialysis

Cancer Network, ONCOLOGY present two part primer report on targeted therapies in solid tumors

White kidney cancer patients have a survival advantage over blacks

Patient recruitment complete for immatics IMA901 Phase 3 trial for renal cell carcinoma

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

Free guide - everything about renal proximal tubule cells eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Free guide - everything about renal proximal tubule cells eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in